InvestmentHealthTech

𲹱ٳձ𳦳Congenicahas closed a £38m Series C funding round.

Based in Cambridge, the firm is a pioneer in the genomic analysisof rare diseases and inherited cancer. It has established a diverse, global customer-base of hospitals, diagnostic laboratories, academic medical centres and pharmaceutical companies.

The new funding is aimed at accelerating international market development and driving further expansion ofDzԲԾ’sproduct platform into somatic cancer, wellness and through partnerships with pharmaceutical companies.

It will also deliver advanced capabilities including the ability to integrate with existing electronic health systems.

The round was co-led by Tencent and Legal & General and included other new investorsXeraya,PuhuaCapital and IDO Investments.

Existing investorsParkwalk, Cambridge Innovation Capital and Downing also participated.

Dr David Atkins, Chief Executive Officer,Congenicasaid: “Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management.

This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors toCongenicaand are grateful to our existing investors for their continued support.”

Dr Ling Ge, Chief European Representative and General ManageratTencent, said: “DzԲԾ’smarket leading technology is designed to enable the delivery of personalised medicine at scale and be fully integrated into routine healthcare customers’ clinical practice on a global basis.

Thisrepresents a significant competitive advantage and the potential to bring genomic medicine into routine use across multiple disease areas driving healthcare systems internationally. We look forward to supportingCongenica as it continues to find innovative solutions to transform healthcare.”